Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12459584 | 0.92 | HDAC1 (0.36) | HDAC1HDAC6SMN1; SMN2GFERNOTUM | |
| SCHEMBL12459569 | 0.92 | NOTUM (0.39) | HDAC1HDAC6SMN1; SMN2PDE4BS1PR5 | |
| SCHEMBL12459591 | 0.92 | PDE4B (0.32) | HDAC1HDAC6PDE4BGFERNOTUM | |
| SCHEMBL12459571 | 0.92 | NOTUM (0.37) | HDAC1HDAC6GFERNOTUM | |
| SCHEMBL12459611 | 0.88 | SMN1; SMN2 (0.37) | HDAC1HDAC6SMN1; SMN2GFER | |
| SCHEMBL12459808 | 0.87 | SMN1; SMN2 (0.39) | HDAC1HDAC6SMN1; SMN2GFERNOTUM | |
| SCHEMBL12459614 | 0.87 | NOTUM (0.38) | HDAC1HDAC6SMN1; SMN2GFERNOTUM | |
| SCHEMBL12459610 | 0.86 | SMN1; SMN2 (0.38) | HDAC1HDAC6SMN1; SMN2GFERNOTUM | |
| SCHEMBL13968984 | 0.86 | NOTUM (0.40) | HDAC1HDAC6SMN1; SMN2PDE4BNOTUM | |
| SCHEMBL12459581 | 0.86 | HDAC1 (0.34) | HDAC1HDAC6SMN1; SMN2PDE4BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2015-02-26 | — | — | US | disclosed |
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2015-02-26 | — | — | US | disclosed |
| EP-2531506-B1 | Spiroindoline compounds for use as anthelminthics | INTERVET INT BV (NL) | 2014-05-14 | — | — | EP | disclosed |
| US-20120295931-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295931-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2011095581-A1 | S PIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHI CS | INTERVET INTERNATIONAL B.V. (NL) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | PKD2, PKD1, PIR | HDAC1 607/4885HDAC6 68/4885SMN1; SMN2 3833/4885 |
| US-20120295931-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | PKD2, PKD1, PIR | HDAC1 607/4885HDAC6 68/4885SMN1; SMN2 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.